Laboratory Corporation of America Holdings (NYSE:LH)‘s stock had its “hold” rating restated by equities research analysts at Jefferies Group LLC in a research report issued on Friday. They currently have a $170.00 target price on the medical research company’s stock. Jefferies Group LLC’s target price indicates a potential upside of 12.05% from the stock’s current price.

A number of other equities research analysts also recently commented on the company. Robert W. Baird reiterated a “hold” rating and set a $166.00 price objective on shares of Laboratory Corporation of America Holdings in a research report on Tuesday. SunTrust Banks, Inc. reiterated a “buy” rating and set a $190.00 price objective on shares of Laboratory Corporation of America Holdings in a research report on Thursday, October 12th. Wells Fargo & Company assumed coverage on Laboratory Corporation of America Holdings in a report on Thursday, October 12th. They issued an “outperform” rating and a $175.00 target price for the company. Zacks Investment Research upgraded Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating and set a $170.00 target price for the company in a report on Tuesday, October 10th. Finally, KeyCorp restated a “hold” rating on shares of Laboratory Corporation of America Holdings in a report on Tuesday, September 26th. Six analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $170.31.

Laboratory Corporation of America Holdings (NYSE:LH) traded up 0.26% during trading on Friday, reaching $151.72. The company’s stock had a trading volume of 692,597 shares. The firm has a market capitalization of $15.45 billion, a P/E ratio of 21.25 and a beta of 0.92. The firm has a 50-day moving average price of $152.76 and a 200-day moving average price of $149.09. Laboratory Corporation of America Holdings has a 52 week low of $119.51 and a 52 week high of $164.22.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.40 by $0.07. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. The company had revenue of $2.50 billion during the quarter, compared to the consensus estimate of $2.47 billion. During the same quarter in the prior year, the firm earned $2.36 EPS. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. On average, equities analysts anticipate that Laboratory Corporation of America Holdings will post $9.51 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/21/laboratory-corporation-of-america-holdings-lh-earns-hold-rating-from-jefferies-group-llc.html.

In other news, CEO David P. King sold 44,687 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $156.86, for a total value of $7,009,602.82. Following the transaction, the chief executive officer now directly owns 258,753 shares of the company’s stock, valued at $40,587,995.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider F Samuel Eberts III sold 31,500 shares of the company’s stock in a transaction on Friday, August 25th. The stock was sold at an average price of $155.22, for a total transaction of $4,889,430.00. Following the completion of the transaction, the insider now directly owns 31,894 shares in the company, valued at $4,950,586.68. The disclosure for this sale can be found here. Insiders sold 222,968 shares of company stock worth $34,980,922 over the last ninety days. 0.90% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Acrospire Investment Management LLC increased its stake in shares of Laboratory Corporation of America Holdings by 16.5% in the second quarter. Acrospire Investment Management LLC now owns 705 shares of the medical research company’s stock worth $109,000 after acquiring an additional 100 shares during the last quarter. Sun Life Financial INC increased its stake in shares of Laboratory Corporation of America Holdings by 9,200.0% in the second quarter. Sun Life Financial INC now owns 744 shares of the medical research company’s stock worth $115,000 after acquiring an additional 736 shares during the last quarter. IFP Advisors Inc increased its stake in shares of Laboratory Corporation of America Holdings by 83.9% in the second quarter. IFP Advisors Inc now owns 1,146 shares of the medical research company’s stock worth $177,000 after acquiring an additional 523 shares during the last quarter. Hourglass Capital LLC acquired a new position in shares of Laboratory Corporation of America Holdings in the second quarter worth $200,000. Finally, Oppenheimer Asset Management Inc. acquired a new position in shares of Laboratory Corporation of America Holdings in the first quarter worth $208,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Analyst Recommendations for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.